Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
This article was originally published in Pharmaceutical Approvals Monthly
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.
You may also be interested in...
At a late-stage pipeline review, Roche execs stressed the advances being made outside the company’s specialty focus on oncology, including neuroscience, inflammation and ophthalmology.
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.